Original language | English (US) |
---|---|
Pages (from-to) | 1220-1225 |
Number of pages | 6 |
Journal | Leukemia and Lymphoma |
Volume | 61 |
Issue number | 5 |
DOIs | |
State | Published - Apr 15 2020 |
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Leukemia and Lymphoma, Vol. 61, No. 5, 15.04.2020, p. 1220-1225.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy
AU - Shallis, Rory M.
AU - Stahl, Maximilian
AU - Wei, Wei
AU - Montesinos, Pau
AU - Lengline, Etienne
AU - Neukirchen, Judith
AU - Bhatt, Vijaya R.
AU - Sekeres, Mikkael A.
AU - Fathi, Amir T.
AU - Konig, Heiko
AU - Luger, Selina
AU - Khan, Irum
AU - Roboz, Gail J.
AU - Cluzeau, Thomas
AU - Martínez-Cuadron, David
AU - Raffoux, Emmanuel
AU - Germing, Ulrich
AU - Umakanthan, Jayadev Manikkam
AU - Mukhereje, Sudipto
AU - Brunner, Andrew M.
AU - Miller, Adam
AU - McMahon, Christine M.
AU - Ritchie, Ellen K.
AU - Rodríguez-Veiga, Rebeca
AU - Itzykson, Raphaël
AU - Boluda, Blanca
AU - Rabian, Florence
AU - Tormo, Mar
AU - Acuña-Cruz, Evelyn
AU - Rabinovich, Emma
AU - Yoo, Brendan
AU - Cano, Isabel
AU - Podoltsev, Nikolai A.
AU - Bewersdorf, Jan Philipp
AU - Gore, Steven
AU - Zeidan, Amer M.
N1 - Funding Information: Amer Zeidan is a Leukemia and Lymphoma Society Scholar in Clinical Research and is also supported by a NCI’s Cancer Clinical Investigator Team Leadership Award (CCITLA). Research reported in this publication was in part supported by the National Cancer Institute of the National Institutes of Health under Award Number P30 CA016359. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We would like to acknowledge all the patients, and the Frederick A. DeLuca Foundation for supporting the statistical analyses. Funding Information: Maximilian Stahl received funding from the MSKCC Clinical Scholars T32 Program under award number 2T32 CA009512-31. Amer Zeidan is a Leukemia and Lymphoma Society Scholar in Clinical Research and is also supported by a NCI?s Cancer Clinical Investigator Team Leadership Award (CCITLA). Research reported in this publication was in part supported by the National Cancer Institute of the National Institutes of Health under Award Number P30 CA016359. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We would like to acknowledge all the patients, and the Frederick A. DeLuca Foundation for supporting the statistical analyses.
PY - 2020/4/15
Y1 - 2020/4/15
UR - http://www.scopus.com/inward/record.url?scp=85080029504&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85080029504&partnerID=8YFLogxK
U2 - 10.1080/10428194.2020.1728753
DO - 10.1080/10428194.2020.1728753
M3 - Letter
C2 - 32100599
AN - SCOPUS:85080029504
SN - 1042-8194
VL - 61
SP - 1220
EP - 1225
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 5
ER -